Abeona Therapeutics Inc. /
Ellodi Pharmaceuticals, L.P.

Abeona Therapeutics Inc. completed its purchase of substantially all assets related to the research, development, manufacture and commercialization of Ellodi Pharmaceuticals, L.P.’s clinical-stage development candidate APT-1011, designed to treat eosinophilic esophagitis.

Consideration included $20 million in value of Abeona Therapeutics Inc. common stock. Additional payments are tied to FDA approval and sales milestones, along with royalties.

1. 9 Nov 2026

   Published by the source